Voyager Therapeutics, Inc.
Voyager Therapeutics (VYGR) is a clinical-stage biotechnology company developing gene therapies for serious neurological diseases. With a market capitalisation of about $275.68M, the firm focuses on adeno-associated virus (AAV)-based delivery platforms designed to provide sustained expression of therapeutic genes to the brain and central nervous system. Investors should know this is a high-risk, high-reward profile typical of small-cap biotechs: value depends heavily on clinical trial outcomes, regulatory decisions and the durability of scientific results. The company’s progress is driven by its pipeline milestones and any collaborations or licensing deals that can bring additional resources. Given the small market cap and clinical-stage assets, shares can be volatile and may react strongly to news. This summary is educational only and not personalised investment advice—prospective investors should review the company’s filings, clinical data and consider suitability given their risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Voyager Therapeutics stock, anticipating significant price growth ahead.
Financial Health
Voyager Therapeutics is producing solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VYGR
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Development Pipeline
Clinical-stage gene therapies drive value and interest, but outcomes are binary and timelines can be long — monitor trial milestones closely.
Platform Technology
AAV-based delivery aims for durable effects in the brain; technological promise exists alongside scientific and regulatory uncertainty.
Market Considerations
Small market cap suggests potential upside but also liquidity and volatility risks; partnerships or licence deals can materially change the outlook.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
